Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cogstate Ltd ( (AU:CGS) ).
Cogstate Ltd reported a substantial increase in revenue and profit for the financial year ending June 30, 2025. The company achieved a 22.3% rise in total revenue, driven largely by a 28.2% increase in clinical trials revenue, while healthcare revenue saw a decline. Profit before income tax nearly doubled, and the company declared its first dividend, indicating strong financial performance and potential positive implications for stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd operates in the healthcare industry, focusing primarily on cognitive science and technology. The company provides cognitive tests and services for clinical trials and healthcare, with a significant emphasis on clinical trials revenue.
Average Trading Volume: 82,586
Technical Sentiment Signal: Buy
Current Market Cap: A$284M
Find detailed analytics on CGS stock on TipRanks’ Stock Analysis page.